Comparison of Clinical Outcomes in Early Stage Triple Negative Breast Cancer Treated With Mastectomy Versus Breast Conserving Therapy

The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients

“…There appeared to be a low risk of bias in the included randomised controlled trials across all domains (Table 4, online only); however, blinding of surgical procedure and radiotherapy receipt was not practicable in this context. The median follow-up period ranged between 1.9 to 7.2 years across the studies and locoregional recurrence was the most commonly assessed endpoint in 9 studies [17,[19][20][21][22][23]25,29,30]. The median age at diagnosis ranged from 50 to 59 years with the largest study including 1,138 TNBC patients [18], and the two smallest [19,30] consisted of 62 TNBC patients each.…”

“…The median follow-up period ranged between 1.9 to 7.2 years across the studies and locoregional recurrence was the most commonly assessed endpoint in 9 studies [17,[19][20][21][22][23]25,29,30]. The median age at diagnosis ranged from 50 to 59 years with the largest study including 1,138 TNBC patients [18], and the two smallest [19,30] consisted of 62 TNBC patients each. In 5 studies, patients who had undergone neoadjuvant chemotherapy prior to surgery were excluded [17,19,25,29,30].…”

“…The median age at diagnosis ranged from 50 to 59 years with the largest study including 1,138 TNBC patients [18], and the two smallest [19,30] consisted of 62 TNBC patients each. In 5 studies, patients who had undergone neoadjuvant chemotherapy prior to surgery were excluded [17,19,25,29,30]. The majority of studies were conducted in the USA or Asia.…”

“…Five studies (1,615 patients) reported on distant recurrence [17,19,21,29,30]. The pooled HR comparing BCT to mastectomy only patients was HR 0.88 (95% CI 0.63, 1.25), Figure 3.…”

“…It is likely that several of these studies were underpowered due to their small sample size [19][20][21]30]. Moreover, potentially important survival differences may exist depending on disease stage [18,22] and age at diagnosis [18].…”